PRCT Court Deadline: PROCEPT BioRobotics Investor Deadline in Securities Fraud Class Action is September 22 – Contact BFA Law if You Lost Money

A securities fraud class action lawsuit has been filed on behalf of Procept investors after its stock plummeted 18% because Procept allegedly artificially inflated its financial performance via an extensive discount program that incentivized customers to place bulk orders.

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation (NASDAQ:PRCT) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws.

If you invested in Procept, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/procept-biorobotics-class-action-lawsuit .

Key Details of the Procept ($PRCT) Class Action:

Lead Plaintiff Deadline: September 22, 2026

Alleged Misconduct: Securities fraud alleging that Procept artificially inflated its financial performance via an extensive discount program that incentivized customers to place bulk orders in excess of underlying procedures

Largest Alleged Stock Drop: February 26-27, 2026 – 18% Stock Drop

Court: U.S. District Court for the Northern District of California

Action: Contact BFA Law to discuss your rights

Investors have until September 22, 2026 to ask the Court to be appointed to lead the case.

The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Procept common stock.

The class action is pending in the U.S. District Court for the Northern District of California. It is captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, et al. , No. 26-cv-7691.

Procept is a medical technology company that sells surgical devices used in the treatment of benign prostatic hyperplasia (BPH) or enlarged prostate.

Procept sells its robotic system as well as handpieces, which are the single-use disposable instruments used during each procedure.

During the relevant period, Procept stated that its handpiece sales were in line with the number of procedures performed.

The company stated that its customers “tend to order as they need [a] product.”

The company also stated that the “differential” between procedures and handpiece sales had “remained relatively consistent.”

As alleged, Procept’s sales were driven by an extensive discount program that incentivized customers to place bulk handpiece orders in excess of underlying procedures.

Procept’s discount program had caused handpiece orders to materially exceed procedures in every quarter during the relevant period.

On August 6, 2025, Procept announced fiscal Q2 2025 results, revealing that handpiece unit shipments had unexpectedly deteriorated.

This news caused the price of Procept stock to decline $7.28 per share, or 16% over a two-day trading period, from a closing price of $45.69 per share on August 6, 2025, to $38.41 per share on August 8, 2025.

On November 4, 2025, Procept announced fiscal Q3 2025 results, revealing that it was reducing annual handpiece sales guidance by 1,000 units and admitted that some customers were “probably carrying too much” inventory.

This news caused the price of Procept stock to decline $3.72 per share, or 10% over a two-day trading period, from a closing price of $35.02 per share on November 4, 2025, to $31.30 per share on November 6, 2025.

Then, on February 25, 2026, Procept announced fiscal Q4 2025 results, revealing that U.S. handpiece unit sales had ma...